• Product nameAnti-Chk2 (phospho T68) antibody
    See all Chk2 primary antibodies
  • Description
    Rabbit polyclonal to Chk2 (phospho T68)
  • Specificityab3501 was tested using MCF7 cells treated with different amounts of doxorubicin (a DNA damaging agent). As the treatment increased the WB signal at 60kDa representing Chk2 increased, indicating that ab3501 was detecting the phosphorylated form of the protein. It has also been shown by peptide ELISA to be specific for the phosphorylated form of the immunizing peptide versus the non-phosphorylated form.
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Chimpanzee
  • Immunogen

    Synthetic peptide: (C)ETVSTpQELYS, corresponding to amino acids 64-73 of Chk2.



Our Abpromise guarantee covers the use of ab3501 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/200 - 1/2000. Detects a band of approximately 61 kDa (predicted molecular weight: 61 kDa).


  • FunctionRegulates cell cycle checkpoints and apoptosis in response to DNA damage, particularly to DNA double-strand breaks. Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', preventing the entry into mitosis. May also play a role in meiosis. Regulates the TP53 tumor suppressor through phosphorylation at 'Thr-18' and 'Ser-20'.
  • Tissue specificityHigh expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.
  • Involvement in diseaseDefects in CHEK2 are associated with Li-Fraumeni syndrome 2 (LFS2) [MIM:609265]; a highly penetrant familial cancer phenotype usually associated with inherited mutations in p53/TP53.
    Defects in CHEK2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
    Defects in CHEK2 are found in some patients with osteogenic sarcoma (OSRC) [MIM:259500].
  • Sequence similaritiesBelongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CHK2 subfamily.
    Contains 1 FHA domain.
    Contains 1 protein kinase domain.
  • Post-translational
    Phosphorylated by PLK4.
  • Cellular localizationNucleus; Nucleus. Isoform 10 is present throughout the cell and Nucleus > PML body. Nucleus > nucleoplasm. Recruited into PML bodies together with TP53.
  • Information by UniProt
  • Database links
  • Alternative names
    • CDS 1 antibody
    • Cds1 antibody
    • Cds1 homolog antibody
    • Checkpoint kinase 2 antibody
    • Checkpoint like protein CHK2 antibody
    • CHEK 2 antibody
    • Chek2 antibody
    • Chk 2 antibody
    • CHK2 checkpoint homolog (S. pombe) antibody
    • CHK2 checkpoint homolog antibody
    • CHK2_HUMAN antibody
    • hCds1 antibody
    • HuCds 1 antibody
    • LFS 2 antibody
    • LFS2 antibody
    • PP1425 antibody
    • RAD 53 antibody
    • RAD53 antibody
    • Rad53 homolog antibody
    • Serine/threonine protein kinase Chk2 antibody
    • Serine/threonine-protein kinase Chk2 antibody
    see all

Anti-Chk2 (phospho T68) antibody images

  • Predicted band size : 61 kDa

References for Anti-Chk2 (phospho T68) antibody (ab3501)

This product has been referenced in:
  • Bertout JA  et al. HIF2{alpha} inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A 106:14391-6 (2009). WB ; Human . Read more (PubMed: 19706526) »
  • Chabalier-Taste C  et al. BRCA1 is regulated by Chk2 in response to spindle damage. Biochim Biophys Acta 1783:2223-33 (2008). Read more (PubMed: 18804494) »

See all 2 Publications for this product

Product Wall

Application Western blot
Loading amount 25 µg
Gel Running Conditions Reduced Denaturing (10%)
Sample Mouse Cell lysate - whole cell (Neural stem cells)
Specification Neural stem cells
Treatment MMS 0,02% Adriamicine 0,5 ´g /mL
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 2% · Temperature: 25°C

Dr. J Igual

Verified customer

Submitted May 08 2014

Thank you very much for your interest in our antibodies against Chk2 phospho Thr68.
To our knowledge, all these three antibodies have not been tested in rodent species. All these three antibodies are however predicted to react against the mouse an...

Read More

Thank you for your enquiry. We have not received any feedback from customers who have tried this antibody for cross-reactivity with mouse. Although it is predicted to cross-react due to 90% sequence homology, we cannot guarantee it. Should you decid...

Read More